These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 6246008)

  • 21. The allogeneic effect on tumor growth. II. Suppression of both ascitic and solid MOPC 315 plasmacytoma by the graft-vs-host reaction, with pathologic correlation.
    Osborne DP; Katz DH
    J Immunol; 1977 Apr; 118(4):1449-55. PubMed ID: 15035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Melphalan-induced enhancement of antitumor immune reactivity in thymocytes of adult BALB/c mice bearing a large MOPC-315 tumor.
    Bartik MM; Takesue BY; Mokyr MB
    Cancer Res; 1987 Sep; 47(18):4848-55. PubMed ID: 3497711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interleukin 2 requirement for the in vitro generation of antitumor cytotoxicity by thymocytes from melphalan-cured MOPC-315 tumor bearers.
    Mokyr MB; Bartik MM; Ahn MC
    Cancer Res; 1989 Feb; 49(4):870-6. PubMed ID: 2783557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. II. Enhancement of in vitro cell-mediated cytotoxicity by combined chemotherapy-immunotherapy.
    Adler A; Keisari Y; Ofir R
    J Natl Cancer Inst; 1985 Feb; 74(2):429-36. PubMed ID: 3856051
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Host response to myeloma: I. Induction of cytotoxic and suppressor T cells by in vivo immunization with MOPC 104E plasmacytoma.
    Miura T; Ghanta VK; Hiramoto RN
    Cancer Invest; 1988; 6(1):29-37. PubMed ID: 2966651
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Common lymphoid progenitors rapidly engraft and protect against lethal murine cytomegalovirus infection after hematopoietic stem cell transplantation.
    Arber C; BitMansour A; Sparer TE; Higgins JP; Mocarski ES; Weissman IL; Shizuru JA; Brown JM
    Blood; 2003 Jul; 102(2):421-8. PubMed ID: 12663447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Normally occurring inhibitory cells for natural killer cell activity. I. Organ distribution.
    Zöller M; Wigzell H
    Cell Immunol; 1982 Nov; 74(1):14-26. PubMed ID: 6218896
    [No Abstract]   [Full Text] [Related]  

  • 28. In vitro stimulation and inhibition of tumor cell growth mediated by different lymphoid cell populations.
    Norbury KC
    Cancer Res; 1977 May; 37(5):1408-15. PubMed ID: 66982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro studies on contact-induced cytotoxicity in mice.
    Mitchell CG
    Transplantation; 1971 Apr; 11(4):359-68. PubMed ID: 4934346
    [No Abstract]   [Full Text] [Related]  

  • 30. The effect of plasmacytomas on serum immunoglobulin levels of BALB/c mice.
    Fenton MR; Havas HF
    J Immunol; 1975 Feb; 114(2 pt 2):793-801. PubMed ID: 1089719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Augmentation of antitumor cytotoxicity of MOPC-315 tumor bearer spleen cells by depletion of dinitrophenol-adherent cells prior to in vitro immunization.
    Mokyr MB; Hengst JC; Przepiorka D; Dray S
    Cancer Res; 1979 Oct; 39(10):3928-34. PubMed ID: 157800
    [No Abstract]   [Full Text] [Related]  

  • 32. Splenic immune effector and suppressor cells in mice bearing a growing plasmacytoma.
    Chen YH; Anderson AB; Williams KG
    Cancer Res; 1985 Nov; 45(11 Pt 1):5473-9. PubMed ID: 2932218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antitumor and therapeutic effects of spleen cells from tumor-bearing mice cultured with T cell growth factor and soluble tumor extract.
    Kan N; Ohgaki K; Inamoto T; Kodama H
    Cancer Immunol Immunother; 1984; 18(3):215-22. PubMed ID: 6334553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyclophosphamide-induced appearance of immunopotentiating T-cells in the spleens of mice bearing a large MOPC-315 tumor.
    Ye QW; Mokyr MB
    Cancer Res; 1984 Sep; 44(9):3873-9. PubMed ID: 6611201
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thyroiditis in T cell-depleted rats: suppression of the autoallergic response by reconstitution with normal lymphoid cells.
    Penhale WJ; Irvine WJ; Inglis JR; Farmer A
    Clin Exp Immunol; 1976 Jul; 25(1):6-16. PubMed ID: 791546
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor neutralization by immune in vitro-sensitized splenocytes depends on an interaction with bone-marrow-derived cells.
    Scuderi P; Rosse C
    Int J Cancer; 1981 Feb; 27(2):213-9. PubMed ID: 7287216
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transforming growth factor-beta-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor eradication following low-dose melphalan therapy.
    Weiskirch LM; Bar-Dagan Y; Mokyr MB
    Cancer Immunol Immunother; 1994 Apr; 38(4):215-24. PubMed ID: 8168116
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Augmentation of natural immunity and regulation of tumor growth by conditioning.
    Ghanta VK; Miura T; Hiramoto NS; Hiramoto RN
    Ann N Y Acad Sci; 1988; 521():29-42. PubMed ID: 3377365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells.
    Herberman RB; Nunn ME; Holden HT; Lavrin DH
    Int J Cancer; 1975 Aug; 16(2):230-9. PubMed ID: 1080480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunoglobulin and other surface antigens of cells of the immune system.
    Takahashi T; Old LJ; McIntire KR; Boyse EA
    J Exp Med; 1971 Oct; 134(4):815-32. PubMed ID: 4106485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.